BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABVC BioPharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ABVC BioPharma's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03833206-853@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:PDC-1421: Phase 1/2 readout est. (NCT03833206)
DESCRIPTION:PDC-1421\, phase 1/2\, Major Depressive Disorder.\nStudy: A Pha
 se I/II Study of PDC-1421 for Treating Depression in Cancer Patients\nEsti
 mated primary completion: 28 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pdc-1421#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03833206
URL:https://assetmemo.bio/drug/pdc-1421#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
